Duclos M, Gatta B, Corcuff J B, Rashedi M, Pehourcq F, Roger P
Laboratoire Neurogénétique et Stress, INSERM U471, Bordeaux, France.
Clin Endocrinol (Oxf). 2001 Oct;55(4):447-54. doi: 10.1046/j.1365-2265.2001.01384.x.
Obesity with abdominal body fat distribution (A-BFD) and hypothalamic-pituitary-adrenal (HPA) axis activity are somehow linked, but the exact interactions still need clarification. Obese subjects display normal circulating plasma cortisol concentrations with normal circadian rhythms. However, when the HPA axis is pharmacologically challenged, body fat distribution matters and then A-BFD obese women differ from those with subcutaneous body fat distribution (P-BFD). We hypothesized that lower dose provocative and suppressive tests than those used to diagnose hypercortisolism of tumour origin or adrenal insufficiency would shed some light on the characteristics of the HPA axis activity in relation with body fat distribution.
Fifty premenopausal obese women were grouped according to their body fat mass distribution. Their plasma cortisol responses to (i) two low doses of dexamethasone (0.25 and 0.5 mg) with (ii) low dose of the ACTH analogue tetracosactrin (1 microg) were assessed. Salivary cortisol was also determined during the ACTH test.
A-BFD differed from P-BFD women in terms of HPA axis responsiveness. They had comparatively: (i) increased nocturnal cortisol excretion (9.38 +/- 2.2 vs. 6.82 +/- 0.91 nmol/micromol creatinine, A-BFD vs. P-BFD, respectively, P = 0.03); (ii) increased salivary cortisol response to ACTH stimulation (1 microg) [salivary cortisol peak: 33.4 (14.1-129) vs. 28.5 (13.2-42.8) nmol/l; salivary AUC: 825 (235-44738) vs. 537 (69-1420) nmol/min/l; A-BFD vs. P-BFD, P = 0.04 for both]; and (iii) increased pituitary sensitivity to dexamethasone testing [postdexamethasone (0.25 mg) plasma cortisol levels: 163 (26-472) vs. 318 (26-652) nmol/l and postdexamethasone (0.5 mg) plasma cortisol levels: 26 (26-79) vs. 33 (26-402) nmol/l; A-BFD vs. P-BFD, P = 0.01 for both).
These data demonstrate differences in the HPA axis activity and sensitivity to glucocorticoids between obese women differing in their body fat distribution, with both enhanced negative and positive feedback in those with abdominal obesity. Several mechanisms may explain these differences: central vs. peripheral hypotheses. Thus, abdominal obesity does not appear to be linked solely to one pathophysiological hypothesis.
肥胖伴腹部体脂分布(A - BFD)与下丘脑 - 垂体 - 肾上腺(HPA)轴活动之间存在某种联系,但确切的相互作用仍需阐明。肥胖受试者的循环血浆皮质醇浓度正常,昼夜节律也正常。然而,当对HPA轴进行药物刺激时,体脂分布很重要,此时A - BFD肥胖女性与皮下体脂分布(P - BFD)的女性不同。我们假设,与用于诊断肿瘤源性皮质醇增多症或肾上腺功能不全的高皮质醇血症的测试相比,较低剂量的激发和抑制测试将有助于揭示HPA轴活动与体脂分布相关的特征。
50名绝经前肥胖女性根据其体脂质量分布进行分组。评估她们对(i)两种低剂量地塞米松(0.25和0.5毫克)以及(ii)低剂量促肾上腺皮质激素类似物二十四肽促皮质素(1微克)的血浆皮质醇反应。在促肾上腺皮质激素测试期间还测定了唾液皮质醇。
A - BFD女性与P - BFD女性在HPA轴反应性方面存在差异。相对而言,她们有:(i)夜间皮质醇排泄增加(分别为9.38±2.2与6.82±0.91纳摩尔/微摩尔肌酐,A - BFD与P - BFD,P = 0.03);(ii)对促肾上腺皮质激素刺激(1微克)的唾液皮质醇反应增加[唾液皮质醇峰值:33.4(14.1 - 129)与28.5(13.2 - 42.8)纳摩尔/升;唾液曲线下面积:825(235 - 44738)与537(69 - 1420)纳摩尔/分钟/升;A - BFD与P - BFD,两者P = 0.04];以及(iii)垂体对地塞米松测试的敏感性增加[地塞米松(0.25毫克)后血浆皮质醇水平:163(26 - 472)与318(26 - 652)纳摩尔/升,地塞米松(